Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry S Sacks

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Annals of Internal Medicine|November 1, 2021
The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second doseHenry S Sacks
Annals of Internal Medicine|January 6, 2026
In older adults, RSV prefusion F vaccine reduced hospitalization for RSV-related respiratory tract disease vs. no vaccineHenry S Sacks,
Annals of Internal Medicine|October 6, 2025
In primary CDI, fecal microbiota transplantation was noninferior to vancomycin for clinical cure at 14 d without recurrence at 60 dHenry S Sacks,
Annals of Internal Medicine|July 5, 2021
The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 dHenry S Sacks
Annals of Internal Medicine|May 6, 2024
In community-acquired pneumonia, adding oral clarithromycin to standard care increased early clinical responseHenry S Sacks
Annals of Internal Medicine|December 5, 2022
In adults, risk for infective endocarditis varied for invasive dental procedures and by antibiotic prophylaxisHenry S Sacks
Annals of Internal Medicine|June 5, 2023
In TB, an 8-wk, 5-drug regimen was noninferior to a standard 24-wk, 4-drug regimen for clinical outcomes at 96 wkHenry S Sacks
Annals of Internal Medicine|March 2, 2026
In older adults, high- vs. standard-dose influenza vaccine reduced hospitalization for influenza or pneumonia in those with CKDHenry S Sacks,
Annals of Internal Medicine|October 19, 2020
Accuracy of point-of-care diagnostic tests for SARS-CoV-2 antibodies (IgM/IgG) is heterogeneousHenry S Sacks
Annals of Internal Medicine|April 4, 2022
In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 dHenry S Sacks
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Annals of Internal Medicine|November 1, 2021
The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second doseHenry S Sacks
Annals of Internal Medicine|January 6, 2026
In older adults, RSV prefusion F vaccine reduced hospitalization for RSV-related respiratory tract disease vs. no vaccineHenry S Sacks,
Annals of Internal Medicine|October 6, 2025
In primary CDI, fecal microbiota transplantation was noninferior to vancomycin for clinical cure at 14 d without recurrence at 60 dHenry S Sacks,
Annals of Internal Medicine|July 5, 2021
The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 dHenry S Sacks
Annals of Internal Medicine|May 6, 2024
In community-acquired pneumonia, adding oral clarithromycin to standard care increased early clinical responseHenry S Sacks
Annals of Internal Medicine|December 5, 2022
In adults, risk for infective endocarditis varied for invasive dental procedures and by antibiotic prophylaxisHenry S Sacks
Annals of Internal Medicine|June 5, 2023
In TB, an 8-wk, 5-drug regimen was noninferior to a standard 24-wk, 4-drug regimen for clinical outcomes at 96 wkHenry S Sacks
Annals of Internal Medicine|March 2, 2026
In older adults, high- vs. standard-dose influenza vaccine reduced hospitalization for influenza or pneumonia in those with CKDHenry S Sacks,
Annals of Internal Medicine|October 19, 2020
Accuracy of point-of-care diagnostic tests for SARS-CoV-2 antibodies (IgM/IgG) is heterogeneousHenry S Sacks
Annals of Internal Medicine|April 4, 2022
In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 dHenry S Sacks
Pageof 4